ADMA saw its Momentum Indicator move below the 0 level on December 04, 2024. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 81 similar instances where the indicator turned negative. In of the 81 cases, the stock moved further down in the following days. The odds of a decline are at .
The 10-day RSI Indicator for ADMA moved out of overbought territory on November 13, 2024. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 43 similar instances where the indicator moved out of overbought territory. In of the 43 cases, the stock moved lower in the following days. This puts the odds of a move lower at .
The Moving Average Convergence Divergence Histogram (MACD) for ADMA turned negative on November 29, 2024. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 50 similar instances when the indicator turned negative. In of the 50 cases the stock turned lower in the days that followed. This puts the odds of success at .
ADMA moved below its 50-day moving average on December 17, 2024 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ADMA declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Aroon Indicator for ADMA entered a downward trend on December 17, 2024. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 6 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where ADMA advanced for three days, in of 263 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. ADMA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (18.975) is normal, around the industry mean (14.664). P/E Ratio (69.000) is within average values for comparable stocks, (87.689). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.783). ADMA has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.012). P/S Ratio (11.574) is also within normal values, averaging (260.687).
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
an operator of a specialty immune globulin, development and commercialization of human plasma and plasma-derived therapeutics
Industry Biotechnology
1 Day | |||
---|---|---|---|
ETFs / NAME | Price $ | Chg $ | Chg % |
UMMA | 24.69 | 0.04 | +0.16% |
Wahed Dow Jones Islamic World ETF | |||
IWDL | 40.71 | N/A | N/A |
ETRACS 2x Leveraged US Value Fctr TR ETN | |||
PTEC | 34.91 | N/A | N/A |
Global X PropTech ETF | |||
HYBB | 46.52 | -0.08 | -0.17% |
iShares BB Rated Corporate Bond ETF | |||
XSOE | 31.47 | -0.17 | -0.54% |
WisdomTree EmMkts ex-Stt-Ownd EntrprsETF |
A.I.dvisor indicates that over the last year, ADMA has been loosely correlated with ATRA. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if ADMA jumps, then ATRA could also see price increases.
Ticker / NAME | Correlation To ADMA | 1D Price Change % | ||
---|---|---|---|---|
ADMA | 100% | -1.84% | ||
ATRA - ADMA | 44% Loosely correlated | -1.52% | ||
RCUS - ADMA | 43% Loosely correlated | -2.60% | ||
ACLX - ADMA | 39% Loosely correlated | -1.67% | ||
ITOS - ADMA | 37% Loosely correlated | -1.03% | ||
LOGC - ADMA | 36% Loosely correlated | -3.62% | ||
More |